Please login to the form below

Not currently logged in
Email:
Password:

SCCHN

This page shows the latest SCCHN news and features for those working in and with pharma, biotech and healthcare.

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles

Lirilumab combination fails to show additional benefit in SCCHN patients. French biotech Innate Pharma says it can’t see a development path forward for its lead cancer drug lirilumab after another ... additional benefit compared to Opdivo alone in

Latest news

More from news
Approximately 6 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics